Aspirin desensitization: Difference between revisions
| Line 48: | Line 48: | ||
==Success of Aspirin Desensitization== | ==Success of Aspirin Desensitization== | ||
Data regarding the success of aspirin desensitization is based upon small observational studies. Patients with [[chronic idiopathic urticaria]] often cannot be desensitized <ref name="pmid15613671">{{cite journal |author=Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA |title=Aspirin sensitivity: implications for patients with coronary artery disease |journal=[[JAMA : the Journal of the American Medical Association]] |volume=292 |issue=24 |pages=3017–23 |year=2004 |month=December |pmid=15613671 |doi=10.1001/jama.292.24.3017 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=15613671 |issn= |accessdate=2010-07-01}}</ref>. | Data regarding the success of aspirin desensitization is based upon small observational studies. Patients with [[chronic idiopathic urticaria]] often cannot be desensitized <ref name="pmid15613671">{{cite journal |author=Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA |title=Aspirin sensitivity: implications for patients with coronary artery disease |journal=[[JAMA : the Journal of the American Medical Association]] |volume=292 |issue=24 |pages=3017–23 |year=2004 |month=December |pmid=15613671 |doi=10.1001/jama.292.24.3017 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=15613671 |issn= |accessdate=2010-07-01}}</ref>. In one single center experience, 23/26 patients (88.5%) could be desensitized<ref name="pmid18328841">{{cite journal |author=Rossini R, Angiolillo DJ, Musumeci G, Scuri P, Invernizzi P, Bass TA, Mihalcsik L, Gavazzi A |title=Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation |journal=[[The American Journal of Cardiology]] |volume=101 |issue=6 |pages=786–9 |year=2008 |month=March |pmid=18328841 |doi=10.1016/j.amjcard.2007.10.045 |url=http://linkinghub.elsevier.com/retrieve/pii/S0002-9149(07)02228-X |issn= |accessdate=2010-07-01}}</ref>. | ||
==Resensitization as a Complications of Aspirin Desensitization== | ==Resensitization as a Complications of Aspirin Desensitization== | ||
Revision as of 17:54, 1 July 2010
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Keri Shafer, M.D.
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Approximately 10% of patients will develop a hypersensitivity reaction to aspirin. Dual antiplatelet therapy with both aspirin and clopidogrel has been associated with improved clinical outcomes in the management of patients with acute coronary syndromes. Although there is a lack of supporting data, patients with aspirin hypersensitivity are sometimes managed with clopidogrel monotherapy. Aspirin desensitization is required when continued aspirin administration is essential (e.g. management of an acute coronary syndrome with stent placement). A rapid protocol can be used as described below. [1]. While this protocol can be implemented over the course of several hours, it is not applicable to those patients who must proceed to the cardiac catheterization laboratory such as the patient with ST segment elevation myocardial infarction where "time is muscle"[2].
Epidemiology and Demographics
In one single center study, among 26 of 1,014 patients admitted for cardiac catheterization had a history of aspirin sensitivity. Of these 26 patients, 61.5% presented with an acute coronary syndrome. While many patients could be desensitized, those with ST elevation MI could not be sensitized before the procedure[2].
Diagnosis
Signs and Symptoms
The signs and symptoms of hypersensitivity include rhinorrhea, exacerbation of asthma, urticaria, angioedema, and anaphylaxis. The majority of patients develop asthma, asthma exacerbation or rhinitis. [3]
History
While aspirin is often the culprit, the reaction can also be induced by cross reaction with cycloxygenase 1 inhibitors (COX 1) such as ibuprofin (Motrin) and naproxen [3].
Mechanism of Aspirin Desensitization
The pathophysiology aspirin hypersensitivity involves both excess leukotriene producation as well as the development of IgE antibodies directed toward aspirin. The goal of a desensitization protocol is to deplete the leukotrienes (as well as other mediators) and to down-regulate the leukotriene receptors.
Protocol for Aspirin Desensitization:
The dose of aspirin is increased every 15 minutes until the maximum dose of aspirin is administered:
Dose
0 minutes: 0.1 mg
15 minutes: 0.3 mg
30 minutes: 1 mg
45 minutes: 3 mg
60 minutes: 10 mg
75 minutes: 20 mg
90 minutes: 40 mg
105 minutes: 81 mg
120 minutes: 162 mg
135 minutes: 325 mg
Success of Aspirin Desensitization
Data regarding the success of aspirin desensitization is based upon small observational studies. Patients with chronic idiopathic urticaria often cannot be desensitized [3]. In one single center experience, 23/26 patients (88.5%) could be desensitized[2].
Resensitization as a Complications of Aspirin Desensitization
If patients are not treated with aspirin chronically after desensitization, they can develop resensitization. A 300 mg daily dose of aspirin was superior to a 100 mg daily dose in preventing resensitization [4].
References
- ↑ Page NA, Schroeder WS (2007). "Rapid desensitization protocols for patients with cardiovascular disease and aspirin hypersensitivity in an era of dual antiplatelet therapy". The Annals of Pharmacotherapy. 41 (1): 61–7. doi:10.1345/aph.1H437. PMID 17200429. Retrieved 2010-07-01. Unknown parameter
|month=ignored (help) - ↑ 2.0 2.1 2.2 Rossini R, Angiolillo DJ, Musumeci G, Scuri P, Invernizzi P, Bass TA, Mihalcsik L, Gavazzi A (2008). "Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation". The American Journal of Cardiology. 101 (6): 786–9. doi:10.1016/j.amjcard.2007.10.045. PMID 18328841. Retrieved 2010-07-01. Unknown parameter
|month=ignored (help) - ↑ 3.0 3.1 3.2 Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA (2004). "Aspirin sensitivity: implications for patients with coronary artery disease". JAMA : the Journal of the American Medical Association. 292 (24): 3017–23. doi:10.1001/jama.292.24.3017. PMID 15613671. Retrieved 2010-07-01. Unknown parameter
|month=ignored (help) - ↑ Rozsasi A, Polzehl D, Deutschle T, Smith E, Wiesmiller K, Riechelmann H, Keck T (2008). "Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily". Allergy. 63 (9): 1228–34. doi:10.1111/j.1398-9995.2008.01658.x. PMID 18699939. Retrieved 2010-07-01. Unknown parameter
|month=ignored (help)